Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 4/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6895946 | 0.90 | HSD17B10 (0.46) | HSD17B10CHRM1ALDH1A1KDM4E | |
| SCHEMBL6891371 | 0.90 | HSD17B10 (0.46) | HSD17B10CHRM1ALDH1A1KDM4E | |
| SCHEMBL27538415 | 0.90 | HSD17B10 (0.46) | HSD17B10CHRM1ALDH1A1KDM4E | |
| SCHEMBL6897088 | 0.89 | HSD17B10 (0.44) | HSD17B10CHRM1ALDH1A1KDM4E | |
| SCHEMBL6898665 | 0.88 | HSD17B10 (0.47) | HSD17B10CHRM1ALDH1A1KDM4E | |
| SCHEMBL6897496 | 0.86 | HSD17B10 (0.45) | HSD17B10CHRM1ALDH1A1KDM4ECHRM3 | |
| Cadaverine Tartrate SCHEMBL6898743 | 0.85 | HSD17B10 (0.41) | HSD17B10CHRM1ALDH1A1KDM4E | |
| SCHEMBL6898126 | 0.85 | HSD17B10 (0.40) | HSD17B10CHRM1ALDH1A1KDM4EPTGES | |
| SCHEMBL6899395 | 0.84 | HSD17B10 (0.49) | HSD17B10CHRM1ALDH1A1KDM4E | |
| SCHEMBL27541920 | 0.84 | HSD17B10 (0.49) | HSD17B10CHRM1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | HSD17B10 1909/4885CHRM1 340/4885ALDH1A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.